Resverlogix (FRA:RFS) Return-on-Tangible-Asset: -261.04% (As of Mar. 2026)


FRA:RFS Resverlogix Corp FRA:RFS
39 GF Score
Price €0.05
! 4 Warning Signs
View Full Analysis

What is Resverlogix Return-on-Tangible-Asset?

Resverlogix FRA:RFS -1.01% 39 Return-on-Tangible-Asset is -261.04% as of Mar. 2026. GuruFocus rates FRA:RFS with a GF Score™ of 39/100. The stock has 4 warning signs investors should review. Among 1,412 Biotechnology companies, Resverlogix ranks worse than 82.65% on this metric.

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Resverlogix's annualized Net Income for the quarter that ended in Mar. 2026 was €-11.94 Mil. Resverlogix's average total tangible assets for the quarter that ended in Mar. 2026 was €4.57 Mil. Therefore, Resverlogix's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was -261.04%.

The historical rank and industry rank for Resverlogix's Return-on-Tangible-Asset or its related term are showing as below:

FRA:RFS' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -1667.49   Med: -188.61   Max: 1089.76
Current: -117.99

During the past 13 years, Resverlogix's highest Return-on-Tangible-Asset was 1089.76%. The lowest was -1667.49%. And the median was -188.61%.

FRA:RFS's Return-on-Tangible-Asset is ranked worse than
82.65% of 1412 companies
in the Biotechnology industry
Industry Median: -35.66 vs FRA:RFS: -117.99

Resverlogix  (FRA:RFS) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Resverlogix Return-on-Tangible-Asset Related Terms


Resverlogix Return-on-Tangible-Asset Historical Data

* Premium members only.

The historical data trend for Resverlogix's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Resverlogix Return-on-Tangible-Asset Chart

Resverlogix Annual Data
Trend Apr16 Apr17 Apr18 Apr19 Apr20 Dec21 Dec22 Dec23 Dec24 Dec25
Return-on-Tangible-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only -319.91 -59.90 -325.51 -171.71 -143.95

Resverlogix Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -396.66 -122.27 -72.83 -15.58 -261.04

FRA:RFS vs VRTX, REGN, ALNY: Return-on-Tangible-Asset Comparison

For the Biotechnology subindustry, Resverlogix's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Resverlogix Return-on-Tangible-Asset vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Resverlogix's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Resverlogix's Return-on-Tangible-Asset falls into.


FRA:RFS
39GF Score
Resverlogix Corp FRA:RFS
Return-on-Tangible-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Resverlogix Return-on-Tangible-Asset Calculation

Resverlogix's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2025 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-6.633/( (4.639+4.577)/ 2 )
=-6.633/4.608
=-143.95 %

Resverlogix's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-11.936/( (4.577+4.568)/ 2 )
=-11.936/4.5725
=-261.04 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Mar. 2026) net income data.

What does a Return-on-Tangible-Asset of -261.04% mean?
Resverlogix (FRA:RFS) has a Return-on-Tangible-Asset of -261.04% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Resverlogix and its competitors. According to the industry distribution chart, Resverlogix ranks #1167 out of 1412 companies in the Biotechnology industry, placing it in the top 82.6%.
Is Resverlogix's Return-on-Tangible-Asset too high?
Resverlogix's current Return-on-Tangible-Asset is -261.04%. Based on the distribution chart, Resverlogix ranks #1167 out of 1412 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Resverlogix has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does Resverlogix's Return-on-Tangible-Asset compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Resverlogix ranks #1167 out of 1412 companies for Return-on-Tangible-Asset. This places Resverlogix in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Biotechnology company?
A good Return-on-Tangible-Asset depends on the Biotechnology industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Resverlogix and its competitors. Resverlogix's current Return-on-Tangible-Asset is -261.04%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Resverlogix stock overvalued right now?
Resverlogix (FRA:RFS) has a current Return-on-Tangible-Asset of -261.04%. The current Return-on-Tangible-Asset is -261.04%. Resverlogix's overall GF Score™ is 39/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Resverlogix (FRA:RFS), the current Return-on-Tangible-Asset is -261.04% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Resverlogix Business Description

Other Exchanges RVXCF:USARVX:Canada
Address 4820 Richard Road SW, Suite 300, Calgary, AB, CAN, T3E 6L1
Resverlogix Corp clinical-stage biotechnology company. The company is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra-terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with chronic disease, including cardiovascular disease (CVD) and associated comorbidities, and COVID-19.
39GF Score

Get the complete analysis for FRA:RFS

Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.05
Price